#USA #New York #FDA #Neogen #HYCOAT

Neogen's Troubling Decline Following FDA Warning

Neogen Corporation, listed on NASDAQ as NEOG, has seen its stock value drop by over 7.2% following a significant warning issued by the FDA regarding one of its veterinary products, HYCOAT. This product has been recalled due to reports of fungal contamination, which has been associated with the unfortunate deaths of at least 20 horses. This incident poses a serious concern not only for horse owners but also for investors worried about the implications on Neogen’s reputation and financial standing.

The FDA's recent tests revealed the presence of various fungal species within HYCOAT, a product that was marketed as sterile. The repercussions of this contamination have extended to nearly 100 horses, causing alarm within the equine community and raising questions about the safety and regulatory compliance of veterinary products.

According to reports from multiple financial news outlets, including Seeking Alpha and Benzinga, the decline in stock value is attributed directly to the FDA's actions and subsequent investigations into the matter. Investors who purchased NEOG shares during this period and who now find themselves facing financial losses may want to consider taking action. Levi & Korsinsky, a law firm specializing in securities litigation, is investigating potential violations of securities law concerning this unsettling event.

The Neogen Vet brand, which includes HYCOAT, is part of the company's Animal Safety segment. In the third quarter of fiscal 2026, this segment reported revenues amounting to $54.5 million, highlighting its significance in Neogen’s overall business operations. However, the ongoing situation raises serious concerns about potential litigation expenses, fines, and impacts on reserves stemming from this product recall.

Investors who find themselves impacted are encouraged to gather necessary documentation of their purchases, including brokerage records showing purchase dates and quantities, in order to assess their eligibility for potential recovery. The firm has assured that investors interested in understanding their legal rights can reach out for a complimentary and obligation-free evaluation.

Frequently Asked Questions

To aid investors, here are some answers to common queries surrounding the Neogen investigation:

• - Who is conducting the investigation?

Levi & Korsinsky LLP is leading the investigation into possible securities law violations associated with the HYCOAT incident.

• - Who qualifies to participate?

Investors who have purchased NEOG stock and suffered losses from the recent downturn are eligible, as eligibility hinges on documented losses rather than current holdings.

• - What should impacted investors do?

Those affected are advised to act promptly to maintain their eligibility for recovery actions. This involves compiling documentation and contacting the investigation team for further guidance.

In conclusion, while the future remains uncertain for Neogen amidst these troubling developments, affected investors have an avenue to pursue potential recovery for their financial losses. With legal experts at their disposal, they can better navigate this complex situation as it unfolds and understand their rights during this trying time.